Tresiba Does Not Have a Traditional Peak
Tresiba (insulin degludec) does not have a distinct peak effect like traditional insulins—instead, it provides a flat, steady glucose-lowering action over its duration. 1
Pharmacodynamic Profile
The glucose-lowering effect of Tresiba demonstrates:
- Maximum effect (GIRmax) occurs at a median of 12 hours post-dose in patients with type 1 diabetes receiving 0.4 units/kg 1
- However, this "maximum" is relatively flat compared to other insulins—the glucose-lowering effect remains relatively constant rather than showing a pronounced peak
- The effect begins approximately 1 hour after injection and lasts at least 42 hours after the last of 8 once-daily injections 1
Pharmacokinetic Characteristics
From an absorption standpoint:
- Maximum insulin degludec concentrations (Cmax) are reached at a median of 9 hours (tmax) after subcutaneous injection 1
- The half-life at steady state is approximately 25 hours, independent of dose 1
- Steady-state levels are achieved after 3-4 days of administration 1
Clinical Implications
The key distinguishing feature of Tresiba is its ultra-long, flat action profile due to its unique mechanism:
- After injection, degludec forms multi-hexamers in subcutaneous tissue creating a depot 1
- Insulin monomers dissociate slowly and continuously from this depot, producing the protracted, peakless profile 1
- This results in 20% day-to-day variability in glucose-lowering effect—significantly more consistent than other basal insulins 1
The clinical takeaway: Unlike NPH insulin (which peaks at 4-10 hours) or even insulin glargine, Tresiba's "peak" at 9-12 hours is minimal and the effect remains relatively flat throughout its 42+ hour duration. This peakless profile is precisely why the risk of hypoglycemia after injection is spread evenly rather than concentrated at a specific time, though the FDA label notes that hypoglycemia risk is generally highest when glucose-lowering effect is maximal 1.